nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A better way to monitor warfarin therapy?
|
Witt, Daniel M. |
|
|
137 |
20 |
p. 2713-2714 |
artikel |
2 |
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas
|
Reimann, Maurice |
|
|
137 |
20 |
p. 2785-2799 |
artikel |
3 |
A new wrinkle for skin dendritic cell migration
|
Cook, Donald N. |
|
|
137 |
20 |
p. 2716-2717 |
artikel |
4 |
Badat M, Davies JOJ, Fisher CA, et al. A remarkable case of HbH disease illustrates the relative contributions of the α-globin enhancers to gene expression. Blood. 2021;137(4):572-575.
|
|
|
|
137 |
20 |
p. 2854 |
artikel |
5 |
Basophilic myeloblasts: a clue for CML blast phase
|
Liu, Huifei |
|
|
137 |
20 |
p. 2852 |
artikel |
6 |
Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML
|
Musani, Rumina |
|
|
137 |
20 |
p. 2853 |
artikel |
7 |
CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation
|
Gallego, Carmen |
|
|
137 |
20 |
p. 2770-2784 |
artikel |
8 |
Editorial Board
|
|
|
|
137 |
20 |
p. i |
artikel |
9 |
Embryonic MK activation: a delicate balance
|
Sola-Visner, Martha |
|
|
137 |
20 |
p. 2714-2715 |
artikel |
10 |
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
|
Klintman, Jenny |
|
|
137 |
20 |
p. 2800-2816 |
artikel |
11 |
Heightened activation of embryonic megakaryocytes causes aneurysms in the developing brain of mice lacking podoplanin
|
Hoover, Christopher |
|
|
137 |
20 |
p. 2756-2769 |
artikel |
12 |
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
|
Ghanima, Waleed |
|
|
137 |
20 |
p. 2736-2744 |
artikel |
13 |
Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study
|
Oskarsdottir, Alma R. |
|
|
137 |
20 |
p. 2745-2755 |
artikel |
14 |
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
|
Thijssen, Rachel |
|
|
137 |
20 |
p. 2721-2735 |
artikel |
15 |
Kinase inhibitors in CLL: drawing the roadmap
|
Fowler, Nathan |
|
|
137 |
20 |
p. 2717-2719 |
artikel |
16 |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
|
Mato, Anthony R. |
|
|
137 |
20 |
p. 2817-2826 |
artikel |
17 |
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
|
Giannis, Dimitrios |
|
|
137 |
20 |
p. 2838-2847 |
artikel |
18 |
Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018
|
Issa, D.E. |
|
|
137 |
20 |
p. 2848-2851 |
artikel |
19 |
Prognosis of comutations in IDH1/2-mutated AML
|
|
|
|
137 |
20 |
p. 2856 |
artikel |
20 |
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study
|
Duchmann, Matthieu |
|
|
137 |
20 |
p. 2827-2837 |
artikel |
21 |
Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021;137(10):1416-1423.
|
|
|
|
137 |
20 |
p. 2854-2855 |
artikel |
22 |
Targeting MCL-1 and BCL-2: a 1-2 punch
|
Brown, Jennifer R. |
|
|
137 |
20 |
p. 2711-2712 |
artikel |
23 |
What can Heraclitus tell us about AML?
|
Ganser, Arnold |
|
|
137 |
20 |
p. 2719-2720 |
artikel |